Maravai LifeSciences Holdings, Inc. (MRVI) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases.
Is Maravai LifeSciences Holdings, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Maravai LifeSciences Holdings, Inc. (MRVI) trades at $7.81 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Maravai LifeSciences Holdings, Inc.
Market cap $2B · 52 weeks $2.83 – $9.00 (13 % below the high) · P/E no earnings · Dividend none · Next earnings November 4, 2026 · expected EPS -$0.06 · Closing price, Oct 30 · accounts published Aug 6.
- Valuation: P/Sales 6.7× (no earnings).
- Balance sheet: Grey zone (watch).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 2.1 %, fails.
- Market cap / Cash 5.2×, fails.
- Cash Runway 45 months, passes.
- Total Debt 0.3×, passes.
- Annual cash burn $0.40, info.
Against its peers (reference peers) — Maravai LifeSciences Holdings, Inc.: P/E —; EV/EBITDA —; ROIC 16.9 %; $2.2B. Bio-Techne Corporation (P/E 62.6×; EV/EBITDA 33.3×; ROIC 7.8 %; $11.4B), Neogen Corporation (P/E —; EV/EBITDA 30.3×; ROIC -0.2 %; $2.6B), Bio-Rad Laboratories, Inc. (P/E 45.1×; EV/EBITDA 20.7×; ROIC 1.5 %; $10.0B).
Profitability
| Return on Equity | -35.42% |
| Return on Invested Capital | 16.91% |
| Return on Assets | -12.82% |
| Gross Margin | 34.61% |
| Operating Margin | 46.02% |
| Net Margin | -37.07% |
Financial Health
| Debt / Equity | 0.86 |
| Current Ratio | 4.05 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 1.98 |
Price Performance
| 1 month | -1.14% |
| 3 months | +21.46% |
| Year-to-date | +140.31% |
| 1 year | +148.73% |
| 3 years | +13.19% |
| 5 years | -82.67% |
Related companies: TECH · RGEN · NEOG · BIO
Explore sector: Healthcare · Biotechnology
More sections of MRVI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks